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Background: Fibroblast growth factor (FGF)-2 has the potential to enhance tendon-to-bone healing 8 
after rotator cuff (RC) injury. 9 
Hypothesis: FGF-2 stimulates tenogenic differentiation of progenitors to improve the biomechanical 10 
strength and histological appearance of repaired RCs in rats. 11 
Study Design: Controlled laboratory study. 12 
Methods: Adult male Sprague-Dawley rats (n = 156) underwent unilateral surgery to repair the 13 
supraspinatus tendon to insertion sites. The FGF-2-treated (gelatin hydrogel containing 5 μg of 14 
FGF-2) and control groups (gelatin hydrogel only) were compared to investigate the effects of FGF-2 15 
at 2, 4, 6, 8, and 12 weeks postoperatively. Biomechanical testing was performed at 6 and 12 weeks. 16 
Semi-quantitative histological analysis and immunohistochemistry for the proliferating cell nuclear 17 
antigen (PCNA) was performed, and the expression of tendon-related markers, including Scleraxis 18 
(Scx) and Tenomodulin (Tnmd) were monitored by real-time reverse transcription polymerase chain 19 
reaction (RT-PCR) and in situ hybridization. SRY-box containing gene 9 (Sox9) expression was 20 
monitored by RT-PCR and immunohistochemistry. At 2 and 4 weeks, immunohistochemistry for 21 
mesenchymal stem cell (MSC) markers were also performed. 22 
Results: The FGF-2-treated group demonstrated a significant improvement in mechanical strength at 23 
6 and 12 weeks and significantly higher histological scores than the control at ≥4 weeks. The average 24 
incidence of PCNA-positive cells was significantly higher at 2 and 4 weeks, and more cells 25 
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expressing MSC markers were detected at the insertion site in the FGF-2-treated group. The 26 
expression level of Scx increased significantly in the FGF-2-treated group from 4 to 8 weeks, while 27 
the Tnmd level increased significantly from 4 to 12 weeks postoperatively. The localization of Tnmd 28 
overlapped with the locations of reparative tissues accompanying collagen fibers with an aligned 29 
orientation. The Sox9 expression was significantly upregulated at 4 weeks in the FGF-2-treated 30 
group. 31 
Conclusion: FGF-2 promotes growth of the tenogenic progenitor cells, which participates in 32 
tendon-to-bone healing, resulting in the biomechanical and histological improvement of repaired RC. 33 
Clinical Relevance: These findings provide clues on the clinical development of regenerative repair 34 
strategies for RC injury. 35 
Key Terms: FGF-2, rotator cuff healing, Scleraxis, Tenomodulin, Sox9, cell proliferation, tenogenic 36 
progenitors 37 
  38 
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What is known about the subject: 39 
Rotator cuff (RC) tears are a common cause of shoulder pain and dysfunction that often require 40 
surgical repair. A relatively high repair failure rate (21.7%, 187/861 patients) was reported in a recent 41 
meta-analysis of 14 studies after RC surgical repair.14 Various efforts (e.g., the application of growth 42 
factors or transplantation of mesenchymal stem cells) have been made to promote a reparative 43 
response.7,8,9,24,28 Administration of the fibroblast growth factor 2 (FGF-2) has the potential to 44 
enhance the reparative response during the RC healing process;9 however, little is known about the 45 
biological mechanism of the repair-promoting effect (improvement of biomechanical strength or 46 
histological appearance) by FGF-2 during RC healing. 47 
  48 
What this study adds to existing knowledge: 49 
In a rat model, the administration of FGF-2 to the healing tendon-bone interface after surgical 50 
repair of an acute supraspinatus injury improved the mechanical strength and histological appearance 51 
between the tendon and bone at ≥4 weeks. Moreover, the proliferation of cells expressing markers of 52 
mesenchymal stem cells was stimulated in the FGF-2-treated group during the early phase of RC 53 
healing. Subsequently, upregulation of the tendon markers such as Scleraxis (Scx) and Tenomodulin 54 
(Tnmd) were detected in the FGF-2-treated group at ≥4 weeks. Interestingly, localization of Tnmd 55 
mRNA overlapped with the locations of reparative tissues accompanying collagen fibers with an 56 
aligned orientation during RC healing. 57 
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This suggests that FGF-2 promotes the growth of tenogenic progenitor cells to participate in 58 
tendon-to-bone healing, resulting in the histological and biomechanical improvement of RC healing. 59 




A rotator cuff (RC) injury is one of the most common causes of shoulder pain and dysfunction, 62 
often requiring surgical repair. Despite great improvement in surgical techniques for repairing RC 63 
tears, a recent meta-analysis of 14 studies reported on an imaging assessment of the structural 64 
integrity of RC repair, and it demonstrated a high rate of failed repair (21.7 %, 187/861 patients) at 65 
the latest follow-up.14 Therefore, developing new strategies for enhancing tendon-to-bone healing is 66 
imperative. 67 
Various growth factors are endogenously expressed during tendon-to-bone healing, suggesting that 68 
they play critical roles in the repair process,27 and there is an interest regarding their use as 69 
therapeutic agents for enhancing RC repairs. Of those, fibroblast growth factor-2 (FGF-2) is a potent 70 
mitogen for a wide variety of cells, including mesenchymal stem cells (MSCs) and progenitor cells.11, 71 
19, 25 We previously demonstrated that the local administration of FGF-2 accelerates the initial 72 
tendon-to-bone healing as indicated by biomechanical tests and histological analyses after 73 
supraspinatus tendon repair in rats.9 However, the biological mechanism of the reparative 74 
enhancement by FGF-2 during RC healing is unclear. 75 
Recently, several genes have been identified as specific tendon markers. Scleraxis (Scx) is a basic 76 
helix-loop-helix transcription factor that is expressed in both tenogenic progenitors and tenocytes.13, 77 
15 Tenomodulin (Tnmd) is a type II transmembrane protein that is specifically expressed in the dense 78 
connective tissues such as tendons and ligaments.17, 18 Tnmd is detected in mature tenocytes and is 79 
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positively regulated by Scx.3, 18 Identification of these marker genes enables us to study the cellular 80 
and molecular events that occur during the establishment of the osteotendinous junction in detail. 81 
Recently, we reported that a subset of Scx-positive progenitors with an expression history of SRY-box 82 
containing gene 9 (Sox9) contributes to the formation of enthesis during development.20 83 
The purpose of this study was to investigate the effects of FGF-2 administration on cell 84 
proliferation and the expression of enthesis-related marker genes (i.e., Scx, Sox9, and Tnmd) during 85 
RC tendon-to-bone healing in rats. The effects on biomechanical strength and histological 86 
appearance during healing were also investigated. We hypothesized that FGF-2 stimulates the 87 
tenogenic differentiation of progenitors and improves the biomechanical strength and histological 88 
appearance of repaired RCs in rats. 89 
  90 
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Materials and Methods 91 
Study Design 92 
This study was approved by our institution’s Animal Studies Committee and the Institutional 93 
Animal Care and Use Committee. We used a rat RC healing model, in which the supraspinatus 94 
tendon insertion site was transected and surgically repaired immediately, to investigate the effects of 95 
FGF-2 on tendon-to-bone healing. In this model, a normal tendon-to-bone insertion site is not 96 
regenerated even after 16 weeks postoperatively.23 97 
We included 156 adult male Sprague-Dawley rats (19–21 weeks old; mean weight, 475 ± 37 g) 98 
that underwent unilateral surgery for supraspinatus tendon repair immediately after transaction, and 99 
they were randomly allocated to the control or FGF-2-treated groups (n = 78 per group). In the 100 
control, gelatin hydrogel sheets (MedGEL Co., Kyoto, Japan) with a phosphate-buffered saline 101 
(PBS) were applied between the supraspinatus tendon and bone. In the FGF-2-treated group, gelatin 102 
hydrogel sheets containing 5 μg of rhFGF-2 (Kaken Pharmaceutical Co., Tokyo, Japan) were applied. 103 
All rats were sacrificed at 2, 4, 6, 8, or 12 weeks postoperatively. At each time point, 6 specimens per 104 
group were used for histological evaluation (i.e., histology, immunohistochemistry, or in situ 105 
hybridization), and 6 per group were analyzed with real-time reverse transcription polymerase chain 106 
reaction (RT-PCR). At 6 and 12 weeks, 9 specimens per group were used for biomechanical testing. 107 
 108 
Local Administration of FGF-2 109 
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We used a biodegradable gelatin hydrogel sheet21 (MedGel PI5, MedGEL Co) as a carrier for 110 
the FGF-2. In our pilot study, three doses of FGF-2 (0.5, 5, and 50 μg/site) in gelatin hydrogel sheets 111 
were compared between the carrier-only and suture-only groups using the same method in the 112 
present study (n = 6 per group underwent histological and biomechanical testing). At 12 weeks 113 
postoperatively, a significant improvement in the ultimate load-to-failure was achieved in all 114 
FGF-2-treated groups (0.5-μg, 29.1 ± 10.1 N; 5-μg, 31.7 ± 8.5 N; and 50-μg, 25.9 ± 8.6 N) compared 115 
to the carrier-only (15.8 ± 4.5 N) and suture-only groups (12.4 ± 2.4 N). The histological scores in 116 
the FGF-2-treated groups (0.5-μg, 9.7 ± 1.0; 5-μg, 10.7 ± 0.5; and 50-μg, 10.3 ± 0.5) were higher 117 
than that in the suture-only (7.5 ± 0.5) and carrier-only groups (7.8 ± 0.8). Although there were no 118 
significant differences among the three FGF-2-treated groups, we used the 5-μg dose of FGF-2, 119 
because the 5-μg FGF-2-treated group showed the highest histological score and the ultimate 120 
load-to-failure. 121 
Before administration, freeze-dried gelatin hydrogel sheets (1 mg) for each shoulder were soaked 122 
with 10 μL of a PBS or FGF-2 (500 μg/mL), and the sheets were incubated for 60 min at room 123 
temperature (RT). 124 
 125 
Surgical Procedure 126 
The rats underwent left shoulder surgery, as previously described.6, 23 Briefly, after the 127 
administration of general anesthesia with an intraperitoneal injection of pentobarbital (25–30 mg/kg), 128 
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longitudinal antero-lateral skin and deltoid muscle incisions were made, and the supraspinatus 129 
tendon was exposure. The supraspinatus tendon was detached sharply at its insertion (3 mm in the 130 
anterior-to-posterior dimension), and the fibrocartilaginous stump on the greater tuberosity was 131 
completely removed using a high-speed bur until bleeding was observed. A 0.8-mm drill hole was 132 
created transversely in an anterior-posterior orientation through the proximal part of the humerus. We 133 
sutured the torn supraspinatus tendon to its anatomic position using a double-armed 5-0 prolene 134 
suture (Ethicon, Somerville, NJ) using a modified Mason-Allen method. A gelatin hydrogel sheet 135 
soaked with PBS or FGF-2 was fixed to the torn end of the tendon using a 5-0 prolene suture, which 136 
is used for repair, and it was secured between the tendon and bone. The incision was closed in layers 137 
with 4-0 nylon sutures. All rats were permitted cage activities without immobilization 138 
postoperatively. 139 
 140 
Biomechanical Testing 141 
As previously described,9, 26 9 animals per group were tested at 6 and 12 weeks postoperatively, 142 
and 9 intact shoulders were used as a normal control. All specimens were frozen at -80°C until 143 
testing. After thawing, the supraspinatus tendon repair to the humerus was dissected from the 144 
surrounding tissues with a custom-designed double scalpel blade to a 2-mm-width to standardize the 145 
tendon tested, and the supraspinatus muscle belly and any scar tissue was removed. Each specimen 146 
was preloaded to 0.1 N and loaded to failure with a conventional tensile tester (STA1225; Orientec, 147 
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Tokyo, Japan) at a rate of 10 mm/min, and the ultimate load-to-failure and the failure site were 148 
recorded. The linear region of the load-displacement curve was used to calculate the stiffness. The 149 
cross-sectional area of the repaired insertion site, including its width and thickness, was measured 150 
using a digital micro-caliper.7 The ultimate load-to-failure was divided by the cross-sectional area of 151 
the repair site to determine the ultimate stress-to-failure. 152 
 153 
Histological Evaluation 154 
The tissues were fixed overnight in 4% paraformaldehyde at an abduction angle of 30° and were 155 
decalcified in Morse’s solution (10% sodium citrate and 22.5% formic acid). After decalcification, 156 
the tissues were dehydrated and were embedded in paraffin. The sections were viewed under an 157 
Olympus BX-51 microscope (Olympus Optical, Tokyo, Japan), and digital images were taken using 158 
a DP70 camera (Olympus Optical). To evaluate healing at the tendon-to-bone site semi-quantitatively, 159 
we used a computerized image analysis (Image J, National Institutes of Health, Bethesda, MD) and a 160 
modified scoring system (Table 1) based on previously reported histological evaluations.24, 26, 28 We 161 
scored the healing insertion site according to three histological parameters (i.e., cellularity, 162 
vascularity, and collagen fiber orientation). Three sequential sections were obtained from each 163 
animal for each staining, and the results were averaged. 164 
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To analyze cellularity, all cell nuclei in a randomly selected region of interest (200 × 200 μm) were 165 
counted to calculate the number per mm2 at the insertion site (100–400 μm proximal to the bone 166 
trough) on hematoxylin and eosin (HE)-stained slides under 100-fold magnification. 167 
To analyze vascularity, all blood vessels were counted to calculate the mean vessel number from 168 
three sequential sections at the insertion site (100–400 μm proximal to the bone trough) on 169 
HE-stained slides under 100-fold magnification. 170 
The collagen fiber orientation was assessed by picrosirius-red stained sections using a polarizing 171 
microscope.7, 26 On eight-bit digitized images, intense white areas of brightly diffracted light on a 172 
gray scale (black, 0; white, 255), were observed. Higher gray scales indicated more organized 173 
collagen fibers. We randomly selected 10 square areas (100 × 100 µm) at the insertion site (100–400 174 
μm proximal to the bone trough) under 12.5-fold magnification, and gray scales were measured 175 
using Image J. The values from the 10 areas were averaged to obtain a value of average gray scales 176 
per specimen. To reduce sampling errors, we took photomicrographs of three sequential sections 177 
from each specimen under the same illumination conditions. 178 
Cellularity and collagen fiber orientation were scored using the percentage of the value measured 179 
in six right shoulders (intact side). A perfect score is 12 points (Table 1). Analysis was performed by 180 
two colleagues who were blinded to the groups for each specimen and the time points throughout the 181 





Semi-serial sections (4 μm) were prepared for immunostaining. To assess the cell proliferation, the 185 
expression of Sox9 and existence of MSCs, we performed immunostaining for PCNA and Sox9 at all 186 
time points, MSC-related surface antigens (CD105, CD90, and CD73), and hematopoietic cell 187 
antigen (CD45 and CD34) at 2 and 4 weeks postoperatively.2 188 
The sections were deparaffinized; rehydrated; and incubated overnight at 4°C with a primary 189 
antibody recognizing PCNA (dilution 1:200, clone PC10; Dakopatts, Copenhagen, Denmark), Sox9 190 
(1:200, AB5535; Millipore, Billerica, MA), CD105 (1:50,#05-1424; Millipore), CD90 (1:200, 191 
AB225; Abcam, Cambridge, MA), CD73 (1:200, AB175396; Abcam), CD45 (1:1000, AB10558; 192 
Abcam), and CD34 (1:100, AB 64480; Abcam). Subsequent reactions were performed using a 193 
peroxidase-labeled antibody (Histofine Simple Stain Max PO; Nichirei, Tokyo, Japan), which 194 
reacted with a 3, 3-diaminobenzidine solution and were counterstained in 0.5% Mayer’s 195 
hematoxylin. 196 
 197 
Estimation of Cell Proliferation and the Expression of Sox9 at the Healing Site 198 
To estimate cell proliferation at the healing site, we modified the previously described method for 199 
PCNA-positive cell counting.12 Three square areas (200 × 200 µm) at the insertion site (100–400 μm 200 
proximal to the bone trough) were selected randomly under 200-fold magnification. The percentage 201 
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of PCNA-positive cells was calculated by dividing the number of PCNA-positive cells by the total 202 
number of cells in the area; the average percentage of three areas from each slide was recorded. 203 
The percentage of Sox9-positive cells was calculated in the same manner. 204 
 205 
RNA Isolation and Real-time Reverse Transcription Polymerase Chain Reaction Analysis 206 
At all time points, the left (operative side) and right (intact side) tendon-to-bone tissues were 207 
dissected and flash frozen in liquid nitrogen and crushed using a Multi-beads Shocker (Yasui Kikai, 208 
Osaka, Japan). After homogenization, total RNA was extracted and purified per the manufacturer’s 209 
instructions using the TRIzol Plus RNA Purification Kit (Invitrogen, Carlsbad, CA). The total RNA 210 
(1 μg) was reverse transcribed to complementary DNA (cDNA) using the Thermoscript RT kit 211 
(Invitrogen). Real-time PCR was performed using an ABI7500 system (Applied Biosystems, Foster, 212 
CA) with TaqMan Universal PCR Master Mix and TaqManTM Gene Expression Assays for the 213 
following genes: Scx (Assay ID: Rn01504576_m1), Tnmd (Rn00574164_m1), Sox9 214 
(Rn01751069_mH), and 18S ribosomal RNA (Rn03928990_g1). Each sample was analyzed in 215 
duplicate. The relative expression levels for the target genes were analyzed using the comparative Ct 216 
method. The delta-Ct values were calculated by the difference between the Ct values of the target 217 
genes and 18S ribosomal RNA. The results are represented as the relative gene expression compared 218 




In situ Hybridization 221 
In situ hybridization was performed to detect the expression of Scx and Tnmd mRNA as previously 222 
described.1 Briefly, 5-μm sections were deparaffinized, rehydrated, incubated with proteinase K (20 223 
μg/mL; Gibco BRL, Rockville, MO), post-fixed in 4% paraformaldehyde, acetylated with 0.1 M 224 
triethanolamine containing 0.25% acetic anhydride for 10 min, dehydrated, and air-dried. 225 
Sense and antisense RNA probes labeled with digoxigenin (DIG) for Scx or Tnmd were 226 
synthesized by in vitro transcription with a DIG RNA labeling kit (Roche, Mannheim, Germany) 227 
using the following cDNA clones: rat Scx cDNA containing a 0.726 kb fragment was subcloned into 228 
pBSII SK+ (Stratagene, La Jolla, CA) and rat Tnmd cDNA containing a 0.607 kb fragment was 229 
subcloned into pCRII-TOPO (Invitrogen), as a template after linearization. Hybridization was 230 
performed at 50°C for 16 h. After hybridization, the sections were washed in 2 × SSC containing 231 
50% formamide, treated with RNase A (20 μg/mL), and washed in 2 × SSC. Immunological probe 232 
detection was performed with an anti-DIG-AP Fab fragment (Roche) and BM Purple (Roche). The 233 
specificity of these antisense probes was confirmed on mouse embryo (E16.5) sections as positive 234 
controls. Sense probes for Scx and Tnmd were used on sections as negative controls. 235 
 236 
Evaluation of the Association between the Locations of Reparative Tissue Accompanying 237 
Collagen Fibers with an Aligned Orientation and Scx or Tnmd mRNA 238 
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To investigate the correlation between the location of healing tissues with aligned collagen fiber 239 
orientation and the localization of Scx or Tnmd mRNA, images from picrosirius-red staining and in 240 
situ hybridization in sections in the treatment and control groups at 8 weeks postoperatively (n = 12) 241 
were evaluated, and nine areas (tendon, suture, and insertion areas of the articular side, middle, and 242 
bursal side) were set (see Figure 5C). Collagen fiber orientation for each area was evaluated by 243 
applying the gray scale as described above. Expression levels of Scx or Tnmd mRNA (density of 244 
hybridization signals) in each area were graded using previously reported23 standards to define high 245 
(4), moderate (3), low (2), and undetectable (1) levels, and the highest grade for each area from each 246 
specimen was recorded. 247 
 248 
Statistical Analysis 249 
Before the study initiation, a power analysis was performed using the G*Power 3.1 program,5 250 
which we used in our pilot study described above that had a similar rat model. A minimum of 9 251 
specimens per group for each time point was required for biomechanical testing (Cohen’s d, ≥1.45), 252 
and a minimum of 6 specimens per group for each time point was required for histological evaluation 253 
(Cohen’s d, ≥2.04), with an α value of 0.05 and a power of 0.80 based on the effect size. The sample 254 
size for real-time RT-PCR was determined according to the power analysis for histological 255 
evaluation. Our primary analysis compared measurements between the groups at each time point, 256 
and the secondary analysis compared measurements within the groups over time. We used 257 
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nonparametric statistical methods for all the analyses, because the data were non-normally 258 
distributed. Statistical significance between the groups at each time point was estimated using the 259 
Mann-Whitney U test. Differences in the measurements within groups over time were analyzed using 260 
the Kruskal-Wallis test, followed by the post-hoc Scheffe test for multiple comparisons. 261 
The correlation between the collagen fiber orientation and the expression levels of Scx or Tnmd 262 
mRNA were assessed using Spearman’s correlation analysis. Values of P < .05 were considered 263 
statistically significant. 264 




Biomechanical Testing 267 
Three of 9 specimens from the normal shoulders failed at the insertion site; the other 6 failed at the 268 
tendon mid-substance. All specimens from the operated groups failed at the site of surgical repair 269 
(Table 2). 270 
At 6 weeks postoperatively, the ultimate load-to-failure, stiffness, and ultimate stress-to-failure 271 
were significantly higher in the FGF-2-treated group than in the control. No significant differences 272 
were observed between the groups in the cross-sectional area of the repair site. 273 
At 12 weeks postoperatively, the ultimate load-to-failure and ultimate stress-to-failure were 274 
significantly higher in the FGF-2-treated group than in the control. No significant differences were 275 
observed between the groups in the stiffness and cross-sectional area of the repair site. 276 
 277 
Histological Analysis 278 
Effects of FGF-2 on the histological appearance 279 
At 2 weeks postoperatively, hyper-cellular and hyper-vascular granulations were noted in the 280 
insertion site (Figure 1A, G), and areas of brightly diffracted polarized light were rarely observed at 281 
the insertion site in any of the groups (Figure 1D, J). 282 
From 6 to 12 weeks, although granulations decreased compared to the previous time point, the 283 
tendon-to-bone area remained hyper-vascular and filled with disorganized collagen fibers in the 284 
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controls (Figure 1B, C, E, F). Conversely, in the FGF-2-treated groups, these granulations were 285 
decreased, and the area of brightly diffracted polarized light at the insertion site was larger than that 286 
in the controls (Figure 1H, I, K, L). The histological differences between the treatment and control 287 
group were observed at ≥4 weeks. 288 
At the bone surface, normal fibrocartilaginous enthesis was not regenerated in any specimen from 289 
any group at any time point. 290 
In both groups, cellularity and vascularity decreased, but the collagen fiber orientation and total 291 
histological scores increased with time (Table 3). The mean number of blood vessels at the insertion 292 
site was significantly smaller in the FGF-2-treated group than in the control at 8 and 12 weeks 293 
postoperatively. Collagen fiber orientation and the total score were significantly higher in the 294 
FGF-2-treated group than in the control at ≥4 weeks. 295 
 296 
Effects of FGF-2 on cell proliferation 297 
At 2 and 4 weeks postoperatively, greater numbers of PCNA-positive cells were observed in the 298 
granulation tissue between the tendon and bone in the FGF-2-treated group than those in the control 299 
(Figure 2A, C). At ≥6 weeks, PCNA-positive cells obviously decreased and were mainly present at 300 
the bone surface in both groups (Figure 2E). The percentage of PCNA-positive cells was 301 
significantly larger in the FGF-2-treated group than in the control at 2 weeks (45.4 ± 9.3% vs. 30.8 ± 302 
5.7%; P = .016) and 4 weeks (41.9 ± 8.0% vs. 29.0 ± 7.4%; P = .025). There were no differences 303 
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between the groups at 6 weeks (control, 21.2 ± 4.6%; FGF-2-treated, 23.8 ± 5.3%; P = .423), 8 304 
weeks (control, 19.7 ± 2.7%; FGF-2-treated, 22.3 ± 5.7%; P = .263) and 12 weeks (control, 19.0 ± 305 
3.8%; FGF-2-treated, 19.6 ± 5.3%; P = .749) (Figure 2E). 306 
 307 
Effect of FGF-2 on the expression of Scx and Tnmd 308 
Real-time RT-PCR analysis showed that a significantly higher expression of Scx was detected in 309 
the FGF-2-treated group than in the control at 4, 6, and 8 weeks (P = .010, .010, and .004, 310 
respectively). There were no differences between the control and FGF-2 groups at 2 and 12 weeks (P 311 
= .631, and .150, respectively) (Figure 3A). Tnmd expression was significantly higher in the 312 
FGF-2-treated group than in the control at 4, 6, 8, and 12 weeks (P = .004, .010, .004, and .016, 313 
respectively). There were no differences between the groups at 2 weeks (P = .631) (Figure 3B). Scx 314 
expression was transiently upregulated from 4 to 8 weeks; meanwhile Tnmd expression was 315 
persistently upregulated by FGF-2 treatment even after 12 weeks postoperatively (Figure 3). 316 
We then performed in situ hybridization to analyze the localization of Scx and Tnmd mRNA. In 317 
both groups, hybridization signals for Scx were detected in the spindle-shaped cells at the tendon 318 
mid-substance at all time points (Figure 4A, C, I, K), and a few hybridization signals for Scx were 319 
detected in the round and spindle-shaped cells within the granulation tissue around the suture at 4, 6, 320 
and 8 weeks (data not shown). In the control, hybridization signals for Scx were rarely detected 321 
within the fibro-vascular tissue at the bone surface at any time points (Figure 4E, G). However, in the 322 
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FGF-2-treated group, Scx were expressed in the spindle-shaped cells at the bone surface at ≥4 weeks 323 
(Figure 4M, O). 324 
Tnmd signals were also detected in the spindle-shaped cells at the tendon mid-substance in both 325 
groups at all time points, and hybridization signals increased with time (Figure 4B, D, J, L). In the 326 
FGF-2-treated group, the distribution of these signals expanded into reparative tissues near the 327 
suturing site compared to the control. However, Tnmd was rarely detected at the bone surface in 328 
either group at any time point (Figure 4F, H, N, P). 329 
 330 
Correlation between the locations of healing tissue with aligned collagen fiber orientation and 331 
Scx or Tnmd mRNA 332 
We assessed 108 areas in both groups at 8 weeks postoperatively (Figure 5). A weak positive 333 
correlation between the location of aligned collagen fiber orientation and expression levels of Scx 334 
mRNA in each area was observed (Spearman’s rank correlation [ρ] = .27, P < .001) (Figure 5D). 335 
Meanwhile, a strong positive correlation between the location of aligned collagen fiber orientation 336 
and the expression levels of Tnmd mRNA in each area was observed (ρ = .88, P < .001) (Figure 5E). 337 
 338 
Effect of FGF-2 on Sox9 expression 339 
Real-time RT-PCR analysis showed that Sox9 expression was significantly higher in the 340 
FGF-2-treated group than in the control at 4 weeks (P = .004). However, at 2, 6, 8 and 12 weeks, 341 
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there were no statistically significant differences between the groups (P = .337, .749, .200 and, .337, 342 
respectively) (Figure 6). 343 
In immunostaining for Sox9 (Figure 7), Sox9-positive cells were mainly observed at the 344 
tendon-to-bone insertion site, but a few Sox9-positive spindle-shaped cells were also detected at the 345 
tendon mid-substance at ≥ 4 weeks in both groups. The percentage of Sox9-positive cells was 346 
significantly higher in the FGF-2-treated group than in the control at 4 weeks (23.7 ± 4.9% vs. 14.0 ± 347 
3.6%; P = .010). There were no differences between the groups at 2 weeks (control, 10.1 ± 4.8%; 348 
FGF-2-treated, 13.4 ± 6.6%; P = .337), 6 weeks (control, 19.7 ± 2.7%; FGF-2-treated, 22.3 ± 5.7%; 349 
P = .263), 8 weeks (control, 10.3 ± 1.1%; FGF-2-treated, 11.2 ± 1.5%; P = .423), and 12 weeks 350 
(control, 10.1 ± 2.6%; FGF-2-treated, 11.3 ± 3.4%; P = .749) (Figure 7I). 351 
 352 
Effect of FGF-2 on mesenchymal stem cells marker-positive cells in the early phase of healing 353 
To analyze MSCs, serial sections were immunostained for MSC-related surface antigens (CD105, 354 
CD90, and CD73) and hematopoietic cell antigen (CD45 and CD34) at 2 and 4 weeks 355 
postoperatively. CD45- and CD34-positive cells were rarely detectable at the insertion site in either 356 
group. In the FGF-2-treated group, cells positive for CD105, CD90, and CD73 were detected more 357 




Our findings support our hypothesis that FGF-2 stimulates the tenogenic differentiation of 360 
progenitors to improve the biomechanical strength and histological appearance of repaired RCs in 361 
rats. Previous studies6, 23 have described the healing response as observed using histological 362 
evaluation in a rat RC acute injury and immediate repair model, and the healing response occurred 363 
almost exclusively within the tendon-to-bone insertion site that was filled with hyper-cellular and 364 
hyper-vascular granulation tissues by postoperative day 10. As healing progresses, cellularity and 365 
vascularity decrease, and then the improvement of collagen fiber orientation and fiber integration 366 
into the bone were observed to some extent. However, a histologically normal tissue is not 367 
regenerated. Instead, the disorganized fibro-vascular scar interposes at the insertion site without 368 
supplementation of growth/differentiation factors.23 Without FGF-2 administration, in this study, the 369 
fibro-vascular scar interposes between the tendon and bone even 12 weeks after RC repair surgery. 370 
In contrast, the administration of FGF-2 clearly decreased the occurrence of fibro-vascular scarring 371 
at the insertion site and increased the aligned orientation of collagen fibers at ≥4 weeks, as indicated 372 
by significantly higher histological scores (Figure 1, Table 3). Moreover, even though normal 373 
biomechanical strength was not achieved at 12 weeks postoperatively (ultimate load-to-failure, 374 
56.7% of normal controls; stiffness, 33.3% of normal controls; ultimate load-to-stress, 35.1% of 375 
normal controls), FGF-2 administration significantly increased the biomechanical strength by 6 376 
weeks postoperatively (Table 2). In an ovine study model on tendon-to-bone healing, the 377 
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disorganized fibro-vascular scar at the insertion site was weaker than the axially-aligned collagen 378 
fibers in the bone.8 These results suggest that the improvement of mechanical strength by FGF-2 379 
treatment is associated with decreases in the fibro-vascular scarring and improvement in the collagen 380 
fiber orientation at the insertion site. 381 
Accumulating evidence suggests that Scx-expressing tenogenic cells can participate in a 382 
regenerative repair of tendons to promote the formation of collagen fibers with an aligned orientation, 383 
which have better tensile strength. Gulotta et al.7 demonstrated that application of bone 384 
marrow-derived MSCs transduced with Scx resulted in an improvement in histological and 385 
biomechanical properties at 4 weeks postoperatively in a similar rat RC healing model. Tan et al.22 386 
also reported that transplantation of Scx-transduced tendon-derived stem cells provided better tendon 387 
repair than that of mock-transduced cells in a rat patellar tendon injury model from the histological 388 
and biomechanical viewpoints. 389 
Our study showed that FGF-2 administration induced Scx expression in the cells of healing tissue 390 
4–8 weeks postoperatively, indicating that more tenogenic progenitor cells were generated at the 391 
healing sites from the mid-to-late stages of healing (Figures 3–4). During differentiation from 392 
tenogenic progenitors to mature tenocytes, the Scx expression declines, while Tnmd is continuously 393 
expressed.10, 18 In murine tendon development, Scx expression increases from E10.5 to E12.5 and 394 
decreases at E13.5, meanwhile the expression of Tnmd sharply increases from E13.5 and persists 395 
until the late stage in the forelimb tendon cells.10 These temporal expression patterns of Scx and 396 
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Tnmd were also demonstrated in mouse patellar healing.16 In this study, Tnmd-positive tenocyte-like 397 
cells were persistently observed until the later stage of healing from 4–12 weeks postoperatively. 398 
Interestingly, Tnmd-positive tenocyte-like cells were only observed in the area with highly oriented 399 
collagen fibers. In particular, these cells were distributed into the reparative tissues near the suturing 400 
site in the FGF-2-treated group 4–12 weeks postoperatively, which was consistent with highly 401 
oriented collagen fiber areas as shown by the histological evaluation in this study (Figure 5E). These 402 
spatial patterns of Tnmd expression are similar to that in the late-stage of tendon development,18 403 
suggesting that Tnmd is a useful marker for evaluating the differentiation of mature tenocyte-like 404 
cells in tendon healing. 405 
Despite enhanced differentiation of Tnmd-positive tenocyte-like cells, it is unlikely that FGF-2 406 
directly stimulated tenogenic differentiation of cells in this later phase of RC healing, since FGF-2 is 407 
known to be released from gelatin hydrogel sheets within 2 weeks.21 Thus, the FGF-2-stimulated 408 
tenogenic repair responses in this study must be primarily mediated by the growth stimulation of 409 
undifferentiated mesenchymal cells, as indicated by a higher incidence of PCNA-positive cells at the 410 
repair sites during the early phase (Figure 2). In a mouse patellar tendon healing model,4 411 
undifferentiated mesenchymal progenitors migrate from a paratenon to the healing site by 1 week 412 
post-injury. Subsequently, Scx-expressing cells appear at ≥2 weeks, suggesting that the initial growth 413 
of undifferentiated mesenchymal progenitors have a critical role for the subsequent tenogenic 414 
differentiation of cells during the later phase of healing. In agreement with the previous in vitro 415 
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studies11, 19, 25 that have shown that FGF-2 potently stimulates the self-renewal of MSCs and/or 416 
progenitor cells without a loss of potentials for the subsequent cell differentiation, we demonstrated 417 
at least in the present study that the healing process started with a better accumulation of cells 418 
expressing MSC-related markers within 2 weeks in the FGF-2-treated group (Figure 8). 419 
There are several limitations to the current study. First, our acutely created tear and immediate 420 
repair model does not reflect chronic degenerative RC tears, and our findings in this rat model may 421 
not directly translate to humans, because the healing processes in healthy animals may not mirror the 422 
situations encountered in clinical practice. However, based on anatomical similarities between 423 
humans, this model has been widely used to investigate the mechanism of healing6, 23, 27 and the 424 
method of healing enhancement.7, 9, 24 Second, this study did not directly identify the function of 425 
tenogenic marker genes during the RC healing process. Further studies using a knockout model on 426 
Scx or Tnmd are required to determine the roles of these genes during the RC healing process. Third, 427 
our findings demonstrated that the biomechanical and histological values of the control group did not 428 
reach those of the FGF-2-treated group by 12 weeks. A longer time period may be necessary to 429 
understand whether the effect observed in the FGF-2-treated group will persist throughout the 430 
healing response. Fourth, the sample size, which was based on the large effect size, was relatively 431 
small, and it may be underpowered to detect significant differences. Likewise, our histological 432 
evaluation may also be underpowered, because it did not include all sections from the specimens. 433 
However, there was little or no discrepancy among our findings observed in various evaluation 434 
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methods during RC healing. Lastly, direct clinical implications for treatment may be difficult to 435 
determine from this small animal model. Currently, little is known about the biological mechanisms 436 
underlying the RC healing response.6 Therefore, basic research on these mechanisms may provide 437 
clues in order to determine the safety, effect, dose, and method of administration in larger models. 438 
Ultimately, human clinical trials are also needed to translate these findings to clinical use. 439 
It is not known whether FGF-2 can selectively facilitate the growth of undifferentiated tenogenic 440 
cells of a certain mesenchymal lineage. However, the enhanced expression of Scx and Tnmd genes in 441 
the mid-to-late stages indicates that a certain microenvironment favorable for the growth response of 442 
tenogenic progenitor cells to FGF-2 may be provided in the present RC healing model. Interestingly, 443 
the transient upregulation of Sox9 detected in the FGF-2-treated group at 4 weeks postoperatively 444 
may indicate that a possible occurrence of Sox9 and Scx double-positive tenogenic progenitors 445 
contributes to enthesis formation during development.20 Thus, further analysis of the cellular 446 
components and the microenvironment at the RC repair sites will help develop clinical strategies for 447 
inducing a specific regenerative healing response in RC injuries. 448 
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Figure legends 527 
Figure 1: Photomicrographs of the specimens at 2, 6 and 12 weeks postoperatively (A–F: control; 528 
G–L: FGF-2-treated). The hematoxylin and eosin-stained sections (A–C, G–I) and picrosirius-red 529 
stained sections under polarized light (D–F, J–L). The boxed areas in A–C and G–I are shown at a 530 
higher magnification in a–c and g–i, respectively. Bars, 200 μm. 531 
 532 
Figure 2: Immunostaining for the proliferating cell nuclear antigen (PCNA) at 2 and 6 weeks 533 
postoperatively (A, B: control; C, D: FGF-2-treated). The sections are counterstained with 534 
hematoxylin. Bars, 100 μm. 535 
The percentage of PCNA-positive cells in the region of interest at the insertion site during rotator 536 
cuff healing (E). Bar graphs, the mean for each group; error bars, one standard deviation. * P < .05, ** 537 
P < .01. 538 
 539 
Figure 3: The gene expression levels of Scleraxis (A) and Tenomodulin (B) in the healing tissues. 540 
The target genes are normalized to 18S ribosomal RNA expression and are further normalized to the 541 
intact supraspinatus tendon tissues that are equal to 1. Bar graphs, the mean for each group; error 542 
bars, one standard deviation. * P < .05, ** P < .01. 543 
 544 
Figure 4: In situ hybridization of Scleraxis and Tenomodulin at the tendon mid-substance (A–F, 545 
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M–R) and the insertion site (G–L, S–X) at 2 and 8 weeks postoperatively (A–L: control; M–X: 546 
FGF-2-treated). Sense, the negative control using a sense labeled probe. Arrows, the hybridization 547 
signals. Bars, 100 μm. 548 
 549 
Figure 5: Picrosirius-red-stained sections under polarized light (A) and in situ hybridization of 550 
Tenomodulin (B) for the FGF-2-treated group at 8 weeks postoperatively. Arrows, the hybridization 551 
signals. Bars, 200 μm. Schematic illustration of the segmented area in healing tissues (C). (t, tendon 552 
areas; s, suture areas; i, insertion areas; a, articular side; m, middle layer; b, bursal side). 553 
Correlation between collagen fiber orientation and the expression levels of Scx mRNA (D), or Tnmd 554 
mRNA (E) for each area in both groups, respectively. Gray scale percentages are relative values 555 
compared to six intact specimens. The correlation coefficient (ρ) and P-value were obtained by 556 
Spearman’s correlation analysis. 557 
 558 
Figure 6: The gene expression levels of Sox9 in the healing tissues. The target genes are normalized 559 
to 18S ribosomal RNA expression and are further normalized to the intact supraspinatus tendon 560 
tissues that are equal to 1. Bar graphs, the mean for each group; error bars, one standard deviation. * 561 
P < .05, ** P < .01. 562 
  563 
Figure 7: Immunostaining for Sox9 at 2, 4, 6, and 12 weeks postoperatively (A–D: control; E–H: 564 
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FGF-2-treated). The percentage of Sox9-positive cells in the region of interest at the insertion site 565 
(G). The sections are counterstained with hematoxylin. Bars, 50 μm. Bar graphs, the mean for each 566 
group; the error bars, one standard deviation. * P < .05, ** P < .01. 567 
 568 
Figure 8: Immunostaining for mesenchymal stem cell-related surface antigens CD105 (A, F), CD90 569 
(B, G), and CD73 (C, H) and hematopoietic cell antigen CD45 (D, I) and CD34 (E, J) at the insertion 570 
site at 2 weeks postoperatively. A–E (control) and F–J (FGF-2-treated) are serial sections 571 
counterstained with hematoxylin. Bars, 50 μm. 572 
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TABLE 1 

































a Number of cells per region of interest from each 
section; percentages represent relative values 
compared to the values from normal 
tendon-to-bone  sections (n = 6), which were set 
at 100%. 
b Number of blood vessels per low PF (100-fold 
magnification) from each section; bv, blood vessel; 
PF, power field. 
c Gray scale per region of interest from each section 
as measured using Image J, percentages represent 
relative values compared to the values from 
normal tendon-to-bone  sections (n = 6), which 
were set at 100%. 
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Table 2 577 
 578 




7.92 ± 2.54 
15.1 ± 3.32 
.009 
 
13.8 ± 4.69b 
23.8 ± 4.61b 
.003 
42.0 ± 5.56 
TABLE 2 
The Summary of The Biomechanical Testinga  
Time point  
group 
6 weeks  
Control (n = 9) 
FGF-2 (n = 9) 
P value 
12 weeks  
Control (n = 9) 
FGF-2 (n = 9) 
P value 
Normal control 
(n = 9) 
aAll values are the mean ± standard deviation. 
bSignificantly different between time points within group (P < .05). 
*Significantly different between groups at the same time point (P < .01). 
Stiffness (N/mm) 
 
3.43 ± 1.24 
7.16 ± 3.28 
.005 
 
6.83 ± 1.25b 
8.98 ± 3.58 
.310 




3.53 ± 0.51 











2.34 ± 0.93 
4.24 ± 0.96 
.001 
 
3.88 ± 1.12b 
6.92 ± 1.10b 
.003 





































TABLE 3  




Control (n = 6) 
FGF-2 (n = 6) 
P value 
4 weeks 
Control (n = 6) 
FGF-2 (n = 6) 
P value 
6 weeks 
Control (n = 6) 
FGF-2 (n = 6) 
P value 
8 weeks 
Control (n = 6) 
FGF-2 (n = 6) 
P value 
12 weeks 
Control (n = 6) 
FGF-2 (n = 6) 
P value 
aAll values are the mean ± standard deviation. 
b Number of cells per region of interest from each section; percentages represent relative values 
compared to the values from normal tendon-to-bone sections (837 ± 86.3 cells/mm2, n = 6), which 
were set to 100%. 
c Number of blood vessels per low PF (100-fold magnification) from each section; bv, blood vessel; PF, 
power field. 
d Gray scale per region of interest from each section as measured using Image J; percentages 
represent relative values compared to the values from normal tendon-to-bone sections (191.0 ± 17.5 
gray scale, n = 6), which were set to 100%. 
e Scores represent a total score of three parameters including cellularity, vascularily and collagen 
fiber orientation. A perfect score in this scoring system is 12 points. 
f-i Significantly different within group compared to 2(f), 4(g), 6(h), and 8 weeks(i), respectively (P 
< .05).  
*Significantly different between groups at the same time point (P < .05).  
Vascularity c 






















Collagen fiber  
orientationd (%) 
 
17.9 ±2.5 
21.6 ±3.7 
.078 
 
41.4 ±10.9f 
56.0 ±3.3f 
.007 
 
57.4 ±5.3f 
68.1 ±4.8f,g 
.025 
 
62.5 ±4.6f-h 
73.4 ±8.1f,g 
.025 
 
70.8 ±6.4f-h 
81.9 ±4.5f-h 
.025 
Total scoree 
 
3.0 ±0.0 
3.2 ±0.4 
.631 
 
4.0 ±0.6 
4.8 ±0.4 
.045 
 
5.2 ±0.4f,g 
6.3 ±1.0f 
.037 
 
5.8 ±0.4e,f 
8.0 ±1.7e,f 
.013 
 
7.2 ±1.0f-i 
9.3 ±1.2f-h 
.013 
 
* 
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